228 related articles for article (PubMed ID: 33794646)
1. Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine.
Rhainds D; Packard CJ; Brodeur MR; Niesor EJ; Sacks FM; Jukema JW; Wright RS; Waters DD; Heinonen T; Black DM; Laghrissi-Thode F; Dubé MP; Pfeffer MA; Tardif JC
Circ Genom Precis Med; 2021 Apr; 14(2):e003219. PubMed ID: 33794646
[TBL] [Abstract][Full Text] [Related]
2. CETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib.
Tardif JC; Rhainds D; Rhéaume E; Dubé MP
Arterioscler Thromb Vasc Biol; 2017 Mar; 37(3):396-400. PubMed ID: 28126828
[TBL] [Abstract][Full Text] [Related]
3. Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib.
Tardif JC; Dubé MP; Pfeffer MA; Waters DD; Koenig W; Maggioni AP; McMurray JJV; Mooser V; White HD; Heinonen T; Black DM; Guertin MC;
Am Heart J; 2020 Apr; 222():157-165. PubMed ID: 32087417
[TBL] [Abstract][Full Text] [Related]
4. Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes.
Tardif JC; Rhainds D; Brodeur M; Feroz Zada Y; Fouodjio R; Provost S; Boulé M; Alem S; Grégoire JC; L'Allier PL; Ibrahim R; Guertin MC; Mongrain I; Olsson AG; Schwartz GG; Rhéaume E; Dubé MP
Circ Cardiovasc Genet; 2016 Aug; 9(4):340-8. PubMed ID: 27418594
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial.
Tardif JC; Pfeffer MA; Kouz S; Koenig W; Maggioni AP; McMurray JJV; Mooser V; Waters DD; Grégoire JC; L'Allier PL; Wouter Jukema J; White HD; Heinonen T; Black DM; Laghrissi-Thode F; Levesque S; Guertin MC; Dubé MP;
Eur Heart J; 2022 Oct; 43(39):3947-3956. PubMed ID: 35856777
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.
Tardif JC; Rhéaume E; Lemieux Perreault LP; Grégoire JC; Feroz Zada Y; Asselin G; Provost S; Barhdadi A; Rhainds D; L'Allier PL; Ibrahim R; Upmanyu R; Niesor EJ; Benghozi R; Suchankova G; Laghrissi-Thode F; Guertin MC; Olsson AG; Mongrain I; Schwartz GG; Dubé MP
Circ Cardiovasc Genet; 2015 Apr; 8(2):372-82. PubMed ID: 25583994
[TBL] [Abstract][Full Text] [Related]
7. A sex-specific evolutionary interaction between
Gamache I; Legault MA; Grenier JC; Sanchez R; Rhéaume E; Asgari S; Barhdadi A; Zada YF; Trochet H; Luo Y; Lecca L; Murray M; Raychaudhuri S; Tardif JC; Dubé MP; Hussin J
Elife; 2021 Oct; 10():. PubMed ID: 34609279
[TBL] [Abstract][Full Text] [Related]
8. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Shinkai H
Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
[TBL] [Abstract][Full Text] [Related]
9. ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.
Nissen SE; Pillai SG; Nicholls SJ; Wolski K; Riesmeyer JS; Weerakkody GJ; Foster WM; McErlean E; Li L; Bhatnagar P; Ruotolo G; Lincoff AM
JAMA Cardiol; 2018 May; 3(5):401-408. PubMed ID: 29525816
[TBL] [Abstract][Full Text] [Related]
10. Advancing Beyond Failed High-density Lipoprotein Clinical Trials to Pharmacogenetic Studies of ADCY9 and Cholesterol Ester Transfer Protein Inhibition.
Black DM; Miller M; Heinonen TM; Zhang G
J Cardiovasc Pharmacol; 2021 Oct; 78(4):496-500. PubMed ID: 34173811
[TBL] [Abstract][Full Text] [Related]
11. ADCY9 (Adenylate Cyclase Type 9) Inactivation Protects From Atherosclerosis Only in the Absence of CETP (Cholesteryl Ester Transfer Protein).
Rautureau Y; Deschambault V; Higgins MÈ; Rivas D; Mecteau M; Geoffroy P; Miquel G; Uy K; Sanchez R; Lavoie V; Brand G; Nault A; Williams PM; Suarez ML; Merlet N; Lapointe L; Duquette N; Gillis MA; Samami S; Mayer G; Pouliot P; Raignault A; Maafi F; Brodeur MR; Levesque S; Guertin MC; Dubé MP; Thorin É; Rhainds D; Rhéaume É; Tardif JC
Circulation; 2018 Oct; 138(16):1677-1692. PubMed ID: 29674325
[TBL] [Abstract][Full Text] [Related]
12. Impact of
Hopewell JC; Ibrahim M; Hill M; Shaw PM; Braunwald E; Blaustein RO; Bowman L; Landray MJ; Sabatine MS; Collins R;
Circulation; 2019 Sep; 140(11):891-898. PubMed ID: 31331193
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?].
Murín J; Pernický M; Kiňová S
Vnitr Lek; 2016; 62(10):789-794. PubMed ID: 27900865
[TBL] [Abstract][Full Text] [Related]
14. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.
Lüscher TF; Taddei S; Kaski JC; Jukema JW; Kallend D; Münzel T; Kastelein JJ; Deanfield JE;
Eur Heart J; 2012 Apr; 33(7):857-65. PubMed ID: 22345126
[TBL] [Abstract][Full Text] [Related]
15. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS;
N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252
[TBL] [Abstract][Full Text] [Related]
16. Dalcetrapib: a review of Phase II data.
Robinson JG
Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
[TBL] [Abstract][Full Text] [Related]
17. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
Rhainds D; Arsenault BJ; Brodeur MR; Tardif JC
Future Cardiol; 2012 Jul; 8(4):513-31. PubMed ID: 22871191
[TBL] [Abstract][Full Text] [Related]
18. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Mohammadpour AH; Akhlaghi F
Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
[TBL] [Abstract][Full Text] [Related]
19. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters.
Briand F; Thieblemont Q; Muzotte E; Burr N; Urbain I; Sulpice T; Johns DG
Eur J Pharmacol; 2014 Oct; 740():135-43. PubMed ID: 25008069
[TBL] [Abstract][Full Text] [Related]
20. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Niesor EJ
Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
